1. Home
  2. Research
  3. Research Groups
  4. Translational Haematology

Translational Haematology

Our Translational Hematology group was created with the aim of generating knowledge in the field of hematology and collaborating with other groups for the implementation of projects. Our activity is based on a broad portfolio of clinical trials, basic research projects and registry studies. The area of ​​knowledge in which we focus is the study of the immune system and its relationship with oncohematological diseases and their infectious complications, cell therapy, study of the adverse effects of drugs and optimization in obtaining and using blood components in Transfusion Therapy

Search for publications

Only original articles, editorials, guidelines.

  • Santaliestra M, Garrote M, Noya MS, Pérez-Encinas M, Senín A, Pérez-López R, Ferrer-Marín F, Carreño-Tarragona G, Caballero G, Magro E, Vélez P, Cortés Vázquez MÁ, Moretó A, Angona A, Pastor-Galán I, Guerra JM, García Hernández C, Mata MI, Stuckey R, Gómez-Casares MT, Fox L, Cuevas B, García-Gutiérrez V, Triguero A, Arellano-Rodrigo E, Hernández-Boluda JC, Alvarez-Larrán A.

    Prognostic value of response to first-line hydroxyurea according to IPSET stratification in essential thrombocythemia.

    Leukemia . 38(12): 2636-2643.

    [doi:10.1038/s41375-024-02416-2]

  • Puig N, Agulló C, Contreras T, Pérez JJ, Aires I, Calasanz MJ, García-Sanz R, Castro S, Martínez-López J, Rodríguez-Otero P, González-Calle V, González MS, Oriol A, Gutiérrez NC, Ríos-Tamayo R, Rosiñol L, Álvarez MÁ, Bargay J, González-Rodríguez AP, Alegre A, Escalante F, Iñigo MB, De la Rubia J, Teruel AI, De Arriba F, Palomera L, Hernández MT, López-Jiménez J, Reinoso M, García-Mateo A, Ocio EM, Bladé J, Lahuerta JJ, Cedena MT, Paiva B, Miguel JFS, Mateos MV.

    Single-point and kinetics of peripheral residual disease by mass spectrometry to predict outcome in patients with high risk smoldering multiple myeloma included in the GEM-CESAR trial.

    Haematologica . 109(12): 4056-4066.

    [doi:10.3324/haematol.2024.285742]

  • Vives S, Quintela D, Morgades M, Cano-Ferri I, Serrano A, Acuña-Cruz E, Cervera M, Díaz-Beyá M, Vidriales B, Raposo-Puglia JÁ, Arnan M, Garrido A, Balerdi A, Cabello AI, Herrera-Puente P, Serrano J, Coll R, Tormo M, López-Marín J, García-Ávila S, Casado MS, Padilla I, Rodríguez-Macías G, Calbacho M, Puchol A, Hernández A, Torres M, Costilla L, Colorado MM, Martínez-Cuadrón D, Esteve J, Montesinos P.

    Salvage Therapy with Second-Generation Inhibitors for FLT3 Mutated Acute Myeloid Leukemia: A Real-World Study by the CETLAM and PETHEMA Groups.

    Cancers . 16(23): .

    [doi:10.3390/cancers16234028]

  • Garcia-Gutierrez V, Huang F, Ashaye A, Dalal M, Laliman-Khara V, Breccia M, Rutherford M, Moradian H, Patos P, Jabbour EJ.

    Ponatinib vs. asciminib in post-second-generation tyrosine kinase inhibitor therapy for chronic-phase chronic myeloid leukemia: a matching-adjusted indirect comparison.

    Frontiers in Oncology . 14: 1455378-1455378.

    [doi:10.3389/fonc.2024.1455378]

  • Rodríguez-Mora S, Sánchez-Menéndez C, Bautista-Carrascosa G, Mateos E, Moreno-Serna L, Megías D, Cantón J, García-Gutiérrez V, Murciano-Antón MA, Cervero M, Spivak A, Planelles V, Coiras M.

    Dasatinib interferes with HIV-1 proviral integration and the inflammatory potential of monocyte-derived macrophages from people with HIV.

    BIOCHEMICAL PHARMACOLOGY . 229: 116512-116512.

    [doi:10.1016/j.bcp.2024.116512]

  • Pérez-Lamas L, Díaz AS, Casterá EM, Soto MH, Coll AP, De Las Heras N, Cortes M, Tenza PV, Pacho MS, Magan AS, Angona A, Cervero C, de Paz R, Cuenca AS, Santaliestra M, Marín JL, Casado LF, García-Gutiérrez V.

    Outcomes of chronic myeloid leukemia patients after therapeutic failure to conventional tyrosine kinase inhibitors and asciminib.

    ANNALS OF HEMATOLOGY . 103(11): 4537-4544.

    [doi:10.1007/s00277-024-05906-6]

  • Pastor-Galán I, Pereira A, Arellano-Rodrigo E, Martín I, Mosquera-Orgueira A, Gómez-Casares MT, Hernández-Sánchez A, Ferrer-Marín F, Mora E, Velez P, Ayala R, Angona A, de Las Heras N, Magro E, Mata-Vázquez MI, Fox ML, González de Villambrosía S, Ramírez MJ, García A, García-Gutiérrez V, Cáceres A, Durán MA, Senín MA, Raya JM, González JA, Cuevas B, Xicoy B, Garrote M, Ferrer B, Pérez-Encinas M, Hernández-Rivas JM, Bellosillo B, Álvarez-Larrán A, Hernández-Boluda JC.

    Impact of somatic gene mutations on the risk of thrombosis in myelofibrosis.

    Leukemia . 38(11): 2483-2486.

    [doi:10.1038/s41375-024-02389-2]

  • Melica G, Luna de Abia A, Shah GL, Devlin S, Corona M, Fein J, Dahi PB, Giralt SA, Lin RJ, Palomba ML, Parascondola A, Park J, Salles G, Saldia A, Scordo M, Shouval R, Perales MA, Seo SK.

    Shift from Widespread to Tailored Antifungal Prophylaxis in Lymphoma Patients Treated with CD19 CAR T Cell Therapy: Results from a Large Retrospective Cohort.

    Transplantation And Cellular Therapy . : .

    [doi:10.1016/j.jtct.2024.10.010]

  • Cederquist GY, Schefflein J, Devlin SM, Shah GL, Shouval R, Hubbeling H, Tringale K, Alarcon Tomas A, Fregonese B, Hajj C, Boardman A, Luna De Abia A, Corona M, Cassanello G, Dahi PB, Lin RJ, Ghione P, Salles G, Perales MA, Palomba ML, Falchi L, Scordo M, Grommes C, Yahalom J, Imber BS.

    CNS bridging radiotherapy achieves rapid cytoreduction before CAR T-cell therapy for aggressive B-cell lymphomas.

    Blood Advances . 8(19): 5192-5199. Number of citations: 4

    [doi:10.1182/bloodadvances.2024013393]

  • Agudo-Quílez P, Martín-Moro F, Antoñana Ugalde S, Blanco-Peláez E, García-Cosío M, Tenelanda A, Lledó Navarro JL, López-Jiménez J, Zamorano Gómez JL.

    Primary Cardiac Aggressive B-Cell Lymphoma Affecting Right Ventricle and Acute Cardiovascular Events: Multidisciplinary Approach.

    Jacc. Case Reports . 29(19): 102562-102562.

    [doi:10.1016/j.jaccas.2024.102562]

  • Gambacorti-Passerini C, Brümmendorf TH, Abruzzese E, Kelly KR, Oehler VG, García-Gutiérrez V, Hjorth-Hansen H, Ernst T, Leip E, Purcell S, Luscan G, Viqueira A, Giles FJ, Hochhaus A.

    Efficacy and safety of bosutinib in previously treated patients with chronic myeloid leukemia: final results from the BYOND trial.

    Leukemia . 38(10): 2162-2170.

    [doi:10.1038/s41375-024-02372-x]

  • Lorenc R, Shouval R, Flynn JR, Devlin SM, Saldia A, De Abia AL, De Lapuerta MC, Tomas AA, Cassanello G, Leslie LA, Rejeski K, Lin RJ, Scordo M, Shah GL, Palomba ML, Salles G, Park J, Giralt SA, Perales MA, Ip A, Dahi PB.

    Subsequent Malignancies After CD19-Targeted Chimeric Antigen Receptor T Cells in Patients With Lymphoma.

    Transplantation And Cellular Therapy . 30(10): 990-1000.

    [doi:10.1016/j.jtct.2024.06.027]

  • Manzanares M, Ramos-Martín F, Rodríguez-Mora S, Casado-Fernández G, Sánchez-Menéndez C, Simón-Rueda A, Mateos E, Cervero M, Spivak AM, Planelles V, Torres M, García-Gutiérrez V, Coiras M.

    Sustained antiviral response against in vitro HIV-1 infection in peripheral blood mononuclear cells from people with chronic myeloid leukemia treated with ponatinib.

    FRONTIERS IN PHARMACOLOGY . 15: 1426974-1426974.

    [doi:10.3389/fphar.2024.1426974]

  • Mateos MV, Martínez-López J, Rodriguez Otero P, González-Calle V, Gonzalez MS, Oriol A, Gutiérrez NC, Ríos-Tamayo R, Rosiñol L, Alvarez Rivas MA, Bargay J, Gonzalez-Rodriguez AP, Alegre A, Escalante F, Iñigo Rodríguez MB, De La Rubia J, Teruel AI, de Arriba F, Palomera L, Hernández MT, Lopez Jiménez J, Reinoso-Segura M, García Mateo A, Ocio EM, Paiva B, Puig N, Cedena MT, Bladé J, Lahuerta JJ, San-Miguel JF.

    Curative Strategy for High-Risk Smoldering Myeloma: Carfilzomib, Lenalidomide, and Dexamethasone (KRd) Followed by Transplant, KRd Consolidation, and Rd Maintenance.

    JOURNAL OF CLINICAL ONCOLOGY . 42(27): 3247-3256. Number of citations: 2

    [doi:10.1200/JCO.23.02771]

  • Chatzikonstantinou T, Scarfò L, Minga E, Karakatsoulis G, Chamou D, Kotaskova J, Iacoboni G, Demosthenous C, Albi E, Alcoceba M, Al-Shemari S, Aurran-Schleinitz T, Bacchiarri F, Chatzileontiadou S, Collado R, Davis Z, de Deus Santos MD, Dimou M, Dmitrieva E, Donaldson D, Dos Santos G, Dreta B, Efstathopoulou M, El-Ashwah S, Enrico A, Frygier A, Galimberti S, Galitzia A, Gimeno E, Guarente V, Guieze R, Harrop S, Hatzimichael E, Herishanu Y, Hernández-Rivas JÁ, Jaksic O, Kalicinska E, Laribi K, Karakus V, Kater AP, Kho B, Kislova M, Konstantinou ?, Koren-Michowitz M, Kotsianidis I, Kubova Z, Labrador J, Lad D, Laurenti L, Longval T, Lopez-Garcia A, Marquet J, Maslejova S, Mayor-Bastida C, Mihaljevic B, Milosevic I, Miras F, Moia R, Morawska M, Nath UK, Navarro-Bailón A, Olivieri J, Panovska-Stavridis I, Papaioannou M, Pierie C, Puiggros A, Reda G, Rigolin GM, Ruchlemer R, Schipani M, Schiwitza A, Shen Y, Shokralla T, Simkovic M, Smirnova S, Soliman DSA, Stilgenbauer S, Tadmor T, Tomic K, Tse E, Vassilakopoulos T, Visentin A, Vitale C, Vrachiolias G, Vukovic V, Walewska R, Xu Z, Yagci M, Yañez L, Yassin M, Zuchnicka J, Oscier D, Gozzetti A, Panagiotidis P, Bosch F, Sportoletti P, Espinet B, Pangalis GA, Popov VM, Mulligan S, Angelopoulou M, Demirkan F, Papajík T, Biderman B, Murru R, Coscia M, Tam C, Cuneo A, Gaidano G, Claus R, Stavroyianni N, Trentin L, Antic D, Smolej L, Kalashnikova OB, Catherwood M, Spacek M, Pospisilova S, Doubek M, Nikitin E, Chatzidimitriou A, Ghia P, Stamatopoulos K.

    Therapeutic strategies and treatment sequencing in patients with chronic lymphocytic leukemia: An international study of ERIC, the European Research Initiative on CLL.

    Hemasphere . 8(9): .

    [doi:10.1002/hem3.70004]

  • Simoes C, Gonzalez C, Vergez F, Sarry A, Bertoli S, Ariceta B, Martínez-Cuadrón D, Bergua JM, Vives S, Algarra L, Tormo M, Martinez P, Serrano J, Herrera P, Ramos F, Salamero O, Lavilla E, Gil C, Lopez-Lorenzo JL, Vidriales MB, Chillon C, Labrador J, Falantes JF, Sayas MJ, Ayala R, Martinez-Lopez J, Villar S, Calasanz MJ, Prosper F, San-Miguel JF, Sanz MÁ, Récher C, Paiva B, Montesinos P.

    Data-driven flow cytometry classification of blast differentiation in older patients with acute myeloid leukemia.

    Blood Neoplasia . 1(3): 100027-100027.

    [doi:10.1016/j.bneo.2024.100027]

  • Garcia-Casanovas A, Bisbe E, Garcia-Altes A, Vizoso A, Duran-Jorda X, Sanchez-Pedrosa G, Barquero M, Colomina MJ, Basora M.

    Hospital variation in quality indicators for patient blood management in total knee and hip arthroplasty: a retrospective cohort study.

    BRITISH JOURNAL OF ANAESTHESIA . 133(3): 637-646.

    [doi:10.1016/j.bja.2024.05.019]

  • Mingot-Castellano ME, Reguera-Ortega JL, Zafra Torres D, Hernani R, Lopez-Godino O, Guerreiro M, Herrero B, López-Corral L, Luna A, Gonzalez-Pinedo L, Chinea-Rodriguez A, Africa-Martín A, Bailen R, Martinez-Cibrian N, Balsalobre P, Filaferro S, Alonso-Saladrigues A, Barba P, Perez-Martinez A, Calbacho M, Perez-Simón JA, Sánchez-Pina JM, On Behalf Of The Spanish Group Of Hematopoietic Transplant And Cell Therapy Get.

    Use of Eltrombopag to Improve Thrombocytopenia and Tranfusion Requirement in Anti-CD19 CAR-T Cell-Treated Patients.

    Journal Of Clinical Medicine . 13(17): .

    [doi:10.3390/jcm13175117]